KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Finished Goods: 2016-2025

Historic Finished Goods for Acadia Pharmaceuticals (ACAD) over the last 10 years, with Sep 2025 value amounting to $25.0 million.

  • Acadia Pharmaceuticals' Finished Goods rose 30.84% to $25.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.0 million, marking a year-over-year increase of 30.84%. This contributed to the annual value of $20.5 million for FY2024, which is 309.14% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Finished Goods of $25.0 million as of Q3 2025, which was up 6.78% from $23.4 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Finished Goods registered a high of $25.0 million during Q3 2025, and its lowest value of $947,000 during Q1 2021.
  • In the last 3 years, Acadia Pharmaceuticals' Finished Goods had a median value of $17.2 million in 2024 and averaged $13.7 million.
  • Its Finished Goods has fluctuated over the past 5 years, first crashed by 60.92% in 2021, then surged by 758.53% in 2024.
  • Quarterly analysis of 5 years shows Acadia Pharmaceuticals' Finished Goods stood at $1.1 million in 2021, then skyrocketed by 72.89% to $1.9 million in 2022, then surged by 159.66% to $5.0 million in 2023, then spiked by 309.14% to $20.5 million in 2024, then spiked by 30.84% to $25.0 million in 2025.
  • Its Finished Goods stands at $25.0 million for Q3 2025, versus $23.4 million for Q2 2025 and $23.9 million for Q1 2025.